Moneycontrol Bureau
Shares of Natco Pharma gained 2 percent intraday Monday after the company and its US-based partner have settled infringement suit with Gilead and others for generic Tamiflu, an antiviral medication.Natco Pharma and Alvogen said they have settled the patent infringement suit filed by Gilead Sciences Inc (the innovator of drug), Hoffmann-La Roche Inc, F. Hoffmann-La Roche and Genentech Inc against Alvogen and Natco in New Jersey District Court.
Natco and Alvogen have partnered on the first abbreviated new drug application (ANDA) containing a paragraph IV certification filed with the US Food and Drug Administration (FDA) for generic versions of Tamiflu oral capsules (oseltamivir phosphate), 30 mg, 45 mg and 75 mg.
FDA granted tentative approval to Natco for generic oseltamivir phosphate capsules on March 14, 2014.
Under terms of settlement, Natco’s partner Alvogen will be able to market oseltamivir phosphate capsules before expiration of pediatric exclusivity period, which is February 23, 2017, they said in a filing to exchanges.
Additionally, Natco Pharma has received approval for generic Daclatasvir in India. The drug is used to treat Hepatitis C.
The company said it will launch Daclatasvir 60 mg at Rs 6,000 & 30 mg at Rs 4,000.The stock closed at Rs 547.50, up Rs 15.35, or 2.88 percent on the BSE.Posted by Sunil Shankar Matkar
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
